Antireflux Surgery in Korea: A Nationwide Study from 2011 to 2014

Gut Liver. 2016 Sep 15;10(5):726-30. doi: 10.5009/gnl15406.

Abstract

Background/aims: Although laparoscopic fundoplication is a well-established therapy for gastroesophageal reflux disease (GERD) in Western countries, the mainstay of GERD treatment in Korea is long-term proton pump inhibitor (PPI) use. The aim of the present study was to evaluate nationwide data regarding antireflux surgery in Korea.

Methods: Data from 2011 to 2014 were collected from the Korean Antireflux Surgery Study Group and then analyzed.

Results: A total of 87 patients underwent laparoscopic fundoplication for the treatment of GERD. Preoperatively, typical symptoms were present in 81 patients (93%) and atypical symptoms were present in 51 patients (59%). Twenty-seven patients (31%) had poor PPI responses. The average surgical time and postoperative hospital stay were 116.3±42.3 minutes and 4.3±3.1 days, respectively. At 3 months after surgery, typical symptoms were completely controlled in 86.3% of patients and partially controlled in 11.7%, whereas atypical symptoms were completely controlled in 63.3% of patients and partially controlled in 23.3%.

Conclusions: This study showed that although atypical symptoms and PPI nonresponders are common, the complete control rates of typical and atypical symptoms were 86.3% and 63.3%, respectively. Laparoscopic fundoplication is an efficacious method of controlling the symptoms of GERD and has an acceptable rate of postoperative morbidity and adverse symptoms.

Keywords: Gastroesophageal reflux disease; Laparoscopic fundoplication; Nationwide Korean data; Proton pump inhibitors.

Publication types

  • Evaluation Study

MeSH terms

  • Adult
  • Aged
  • Female
  • Fundoplication / methods
  • Fundoplication / statistics & numerical data*
  • Gastroesophageal Reflux / drug therapy
  • Gastroesophageal Reflux / surgery*
  • Humans
  • Laparoscopy / methods
  • Laparoscopy / statistics & numerical data*
  • Male
  • Middle Aged
  • Proton Pump Inhibitors / therapeutic use
  • Republic of Korea
  • Treatment Outcome

Substances

  • Proton Pump Inhibitors